Main |
Browse Volumes |
Forthcoming Volumes |
Annals PrePrints |
Annals Extra |
E-mail Alerts |
Subscriptions & Orders |
New Proposals |
Author Guidelines |
About Annals |
Help |
 |
|
|
|
|
|
Part V. Novel Targets for Cancer Therapy |
FAK Signaling in Neoplastic Disorders
A Linkage between Inflammation and Cancer
NAING NAING MONa,
SATOKO ITOa,
TAKESHI SENGAa AND
MICHINARI HAMAGUCHIa
a Division of Cancer Biology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa ku, Nagoya, Japan
Key Words: focal adhesion kinase • matrix metalloproteinases • TNF-  • cancer • invasion
Address for correspondence: Michinari Hamaguchi, Division of Cancer Biology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa ku, Nagoya 466, Japan. Voice: +81-52-744-2462; fax: +81-52-744-2464. e-mail: mhamagu{at}med.nagoya-u.ac.jp
Focal adhesion kinase (FAK), a nonreceptor protein tyrosine kinase, is frequently overexpressed in various tumors and its expression shows good correlation with the progression of tumor. FAK is involved in a diverse range of critical cellular events including spreading, proliferation, migration, and invasion. In addition to these cellular functions, we found that FAK signaling played a critical role in the production of matrix metalloproteinases (MMP) such as MMP-2 and MMP-9 and subsequently activated tumor invasion. Moreover, we found that tumor necrosis factor- ( TNF-), a proinflammatory cytokine that acts as an endogenous tumor promoter, activated FAK signaling and enhanced tumor invasion. Since the tumor microenvironment that is largely orchestrated by cytokines is a critical component of tumor progression, these results suggest the importance of FAK as a signaling molecule involved in tumorigenesis. Here, we review the general structure and binding partners of FAK, its regulatory mechanism, and expression in tumors. By summarizing our recent studies, we focus on the critical role of FAK that links cancer with inflammation.
This article has been cited by other articles:
|
|
|
|
 
T. Sittler, J. Zhou, J. Park, N. K. Yuen, S. Sarantopoulos, J. Mollick, R. Salgia, A. Giobbie-Hurder, G. Dranoff, and F. S. Hodi
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Clin. Cancer Res.,
June 15, 2008;
14(12):
3896 - 3905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Zhang, P. G. Knyazev, Y. V. Cheburkin, K. Sharma, Y. P. Knyazev, L. Orfi, I. Szabadkai, H. Daub, G. Keri, and A. Ullrich
AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Cancer Res.,
March 15, 2008;
68(6):
1905 - 1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kokuryo, T. Senga, Y. Yokoyama, M. Nagino, Y. Nimura, and M. Hamaguchi
Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma
Cancer Res.,
October 15, 2007;
67(20):
9637 - 9642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.R.M. Ruhul Amin, M. H. Uddin Biswas, T. Senga, G.-S. Feng, R. Kannagi, M. L. Agarwal, and M. Hamaguchi
A role for SHPS-1/SIRP{alpha} in Concanavalin A-dependent production of MMP-9
Genes Cells,
September 1, 2007;
12(9):
1023 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
